Journal
ACS CHEMICAL BIOLOGY
Volume 10, Issue 9, Pages 2099-2107Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acschembio.5b00174
Keywords
-
Categories
Funding
- DFG (German Research Society) [PE 1605/2-1]
- Medical Research Council [MC_UU_12016/2, MC_U127070193] Funding Source: researchfish
- MRC [MC_U127070193, MC_UU_12016/2] Funding Source: UKRI
Ask authors/readers for more resources
In this study, we report on novel photoactivatable caged prodrugs of vemurafenib. This kinase inhibitor was the first approved drug for the personalized treatment of BRAF-mutated melanoma and showed impressive results in clinical studies. However, the occurrence of severe side effects and drug resistance illustrates the urgent need for innovative therapeutic approaches. To conquer these limitations, we implemented photoremovable protecting groups into vemurafenib. In general, this caging concept provides spatial and temporal control over the activation of molecules triggered by ultraviolet light. Thus, higher inhibitor concentrations in tumor tissues might be reached with less systemic effects. Our study describes the first development of caged vemurafenib prodrugs useful as pharmacological tools. We investigated their photochemical characteristics and photoactivation. In vitro evaluation proved the intended loss-of-function and the light-dependent recovery of efficacy in kinase and cellular assays. The reported vemurafenib photo prodrugs represent a powerful biological tool for novel pharmacological approaches in cancer research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available